Physician profile
Richard Bird
NPI 1265435473
$7,043.30
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $376 · 2021: $2,533 · 2022: $2,445 · 2023: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $998.58 | 2021-2023 | Austedo, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $670.56 | 2021 | |
| Abbvie INC. | $570.53 | 2021-2023 | Qulipta, Ubrelvy, Botox |
| Biohaven Pharmaceutical Holding Company LTD. | $522.38 | 2022 | |
| Biogen, INC. | $348.34 | 2020-2023 | Tysabri, Vumerity, Tysabri |
| Lilly USA, LLC | $328.92 | 2020-2023 | Emgality, Reyvow |
| Neurocrine Biosciences, INC. | $300.20 | 2019-2023 | Ongentys, Ingrezza |
| Amgen INC. | $258.96 | 2019-2022 | |
| Eisai INC. | $256.75 | 2020-2023 | |
| Horizon Therapeutics Plc | $237.55 | 2021-2023 | Uplizna |
| Sunovion Pharmaceuticals INC. | $228.84 | 2020-2022 | |
| Emd Serono, INC. | $213.30 | 2021-2023 | Mavenclad |
| Lundbeck LLC | $210.44 | 2021-2023 | Vyepti |
| Novartis Pharmaceuticals Corporation | $209.34 | 2019-2022 | |
| Ucb, INC. | $173.35 | 2021-2023 | Briviact |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.